These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34710314)

  • 1. Importance of blinding and expectations in opioid-induced constipation: evidence from a randomized controlled trial.
    Sieg M; Mark EB; Drewes AM; Vase L
    Scand J Pain; 2022 Apr; 22(2):410-416. PubMed ID: 34710314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD006332. PubMed ID: 36106667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers.
    Mark EB; Nedergaard RB; Hansen TM; Nissen TD; Frøkjaer JB; Scott SM; Krogh K; Drewes AM
    Neurogastroenterol Motil; 2021 Nov; 33(11):e14131. PubMed ID: 34051122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain.
    Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S
    Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid-induced bowel dysfunction in healthy volunteers assessed with questionnaires and MRI.
    Nilsson M; Poulsen JL; Brock C; Sandberg TH; Gram M; Frøkjær JB; Krogh K; Drewes AM
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):514-24. PubMed ID: 26795566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
    Simpson K; Leyendecker P; Hopp M; Müller-Lissner S; Löwenstein O; De Andrés J; Troy Ferrarons J; Bosse B; Krain B; Nichols T; Kremers W; Reimer K
    Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
    Etropolski M; Kelly K; Okamoto A; Rauschkolb C
    Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid-induced constipation in chronic pain: Experience with 180 patients.
    Velázquez Rivera I; Velázquez Clavarana L; García Velasco P; Melero Ramos C
    J Opioid Manag; 2019; 15(1):69-76. PubMed ID: 30855724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
    Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment.
    Kokki M; Kuronen M; Naaranlahti T; Nyyssönen T; Pikkarainen I; Savolainen S; Kokki H
    Adv Ther; 2017 Jan; 34(1):236-251. PubMed ID: 27921252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a mechanistic study in healthy volunteers.
    Mark EB; Frøkjær JB; Hansen TM; Nedergaard RB; Drewes AM
    Scand J Pain; 2021 Apr; 21(2):406-414. PubMed ID: 33606931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of subjective and objective measures of constipation - Employing a new method for categorizing gastrointestinal symptoms.
    Grønlund D; Vase L; Knudsen SA; Christensen M; Drewes AM; Olesen AE
    J Pharmacol Toxicol Methods; 2018; 94(Pt 2):23-28. PubMed ID: 30149126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids.
    Mark EB; Klinge MW; Grønlund D; Poulsen JL; Schlageter V; Scott SM; Krogh K; Drewes AM
    Neurogastroenterol Motil; 2020 Mar; 32(3):e13753. PubMed ID: 31721398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI analysis of fecal volume and dryness: Validation study using an experimental oxycodone-induced constipation model.
    Mark EB; Bødker MB; Grønlund D; Østergaard LR; Frøkjaer JB; Drewes AM
    J Magn Reson Imaging; 2019 Sep; 50(3):733-745. PubMed ID: 30609164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term oxycodone treatment does not affect electrogenic ion transport in isolated mucosa from the human rectosigmoid colon.
    Nilsson M; Brock C; Poulsen JL; Bindslev N; Hansen MB; Louring Christrup L; Drewes AM
    Scand J Gastroenterol; 2016; 51(5):538-47. PubMed ID: 26610166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction.
    Grønlund D; Poulsen JL; Krogh K; Brock C; Liao D; Gregersen H; Drewes AM; Olesen AE
    Eur J Pharm Sci; 2018 May; 117():187-192. PubMed ID: 29432808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.
    Burness CB; Keating GM
    Drugs; 2014 Mar; 74(3):353-75. PubMed ID: 24452879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.
    Vorsanger G; Xiang J; Biondi D; Upmalis D; Delfgaauw J; Allard R; Moskovitz B
    Pain Res Manag; 2011; 16(4):245-51. PubMed ID: 22059194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.